Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran

BMC Res Notes. 2020 Aug 10;13(1):380. doi: 10.1186/s13104-020-05224-w.

Abstract

Objective: Multi and extensively drug-resistant (MDR and XDR), Pseudomonas aeruginosa (P. aeruginosa) and Acinetobacter baumannii (A. baumannii) are two main causative agents of nosocomial infections leading to increased morbidity and mortality. We aim to study the prevalence of MDR and XDR-A. baumannii and P. aeruginosa phenotypes in clinical specimens. We conducted this for 1 year (2017-2018) and isolated bacteria from the clinical samples. Then, XDR and MDR strains were determined by susceptibility testing (disc diffusion).

Results: Out of 3248 clinical samples, A. baumannii and P. aeruginosa strains were detected in 309(9.51%) of them. Susceptibility testing indicated that (16.50%) and (15.53%) of the P. aeruginosa and (74.75%) and (73.13%) of the A. baumannii isolates were screened as the MDR and XDR strains. The frequency of MDR isolates was higher in wound samples 222 (71.8%). This rate in behavioral intensive care unit (BICU) and restoration ward, were 187 (60.5%) and 63 (20.4%). The frequency of XDR isolates in BICU 187 (59.54%), restoration 58(18.77%), and burns 30 (9.70%) were assessed as well. Considering high isolation rates of MDR and XDR of mentioned strains, it is necessary to apply prevention criteria for eradication of the mentioned bacteria from hospital wards.

Keywords: Acinetobacter baumannii; Carbapenem resistant A. baumannii; Extensively-drug resistant (XDR); Multi-drug resistant (MDR); Nosocomial infections; Pseudomonas aeruginosa.

MeSH terms

  • Acinetobacter Infections* / drug therapy
  • Acinetobacter Infections* / epidemiology
  • Acinetobacter baumannii* / genetics
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • Iran / epidemiology
  • Microbial Sensitivity Tests
  • Pharmaceutical Preparations*
  • Phenotype
  • Prevalence
  • Pseudomonas aeruginosa

Substances

  • Anti-Bacterial Agents
  • Pharmaceutical Preparations